Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AMG 427|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 427||AMG-427|AMG427|BiTE Antibody AMG 427|Anti-FLT3 x Anti-CD3 BiTE AMG 427||CD3 Antibody 20||AMG 427 is a bi-specific T-cell engager (BiTE) antibody that binds to FLT3 and CD3, which activates cytotoxic T-lymphocytes against tumor cells expressing FLT3, potentially resulting in increased death of FLT3-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03541369||Phase I||AMG 427||Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)||Recruiting|